Currax Announces TV Campaign for Contrave

Stock.adobe.com

For many people, losing weight is more difficult that just reducing their caloric intake. While doing so will result in weight loss in healthy adults, actually achieving this can be much more difficult for certain people. Eating habits and hunger pangs can be impacted by a wide variety of factors, such as emotional stimuli.

Currax Pharmaceuticals produces a drug named Contrave that targets these hunger-causing stimuli to help promote healthy weight loss in patients. The company recently announced that it is launching a new ad campaign for the oral medication that focuses on the drug’s ability to reduce cravings.¹ As a result, the campaign is titled “Cravings Don’t Own Me” and will be the first ad campaign for the medication to run on TV.

In a press release from Currax, Dr. Angela Golden, DNP, said, “Uncontrolled cravings are a significant barrier to weight loss that often goes unaddressed in obesity management conversations. The 'Cravings Don't Own Me' campaign sends a strong message: you're not alone in your efforts, and there are effective, affordable options to help you achieve your goals."

The press release also included a quote from a patient ambassador named Jennifer, which says, “I needed to stop obsessing about food and break the cycle of cravings and overeating. Contrave helped me lose weight and keep it off. I was able to reduce my cravings for things like sweets. It helps me focus on making better choices, prioritizing my health, and seeing successful results."

This is the latest weight-loss focused campaign from Currax. In September of 2024, the company launched a similar campaign that centered on food noise.² This is a condition that causes people to have constant and difficult to suppress thoughts about food. As a result, they struggle to maintain healthy eating habits.

In a press release issued at the time, My Weight-What to Know founder Ansley Dalbo said, “We've heard from so many people living with obesity that dealing with constant "food noise" is a significant challenge for them in everyday life. These persistent thoughts about food can impact mental health and can also make weight management more difficult. Recognizing this is a critical first step in combatting weight bias (both internal and external) and de-stigmatizing the choice to seek medical help for obesity."

In September, 2024, Currax announced the results of a Cardiovascular Health Outcomes Analysis that compared Contrave with a similar group of medications.³ According to the results of the analysis, Contrave provides no excess risk of cardiovascular events. The study included 24,600 people with an average patient-follow-up of four-and-a-half years.

In a press release issued at the time, the study’s presenting author and senior managing scientist at Exponent Dustin Burns, PhD, GStat, said, “The study's results found no evidence of increase in cardiovascular risk among initiators of CONTRAVE, which is informative for healthcare providers and patients considering this treatment option for obesity.”

Michael Kyle, MD, senior vice president and chief medical officer at Currax Pharmaceuticals added, “We are honored to have Dr. Burns present these favorable findings at ISPE. Achieving this milestone and the affirmation of the cardiovascular safety of Contrave is gratifying. Over the past four years, we worked exhaustively with regulatory agencies to fully characterize the cardiovascular safety of the product and these results are another proof-point of the positive benefit-risk of Contrave/Mysimba."

Sources

1. Currax Introduces First CONTRAVE® TV Ad and "Cravings Don't Own Me" Campaign, Highlighting Food Cravings Management and Weight Loss. Currax Pharmaceuticals LLC. January 2, 2025. https://www.prnewswire.com/news-releases/currax-introduces-first-contrave-tv-ad-and-cravings-dont-own-me-campaign-highlighting-food-cravings-management-and-weight-loss-302340410.html
2. Currax Pharmaceuticals Unveils New Disease Awareness Campaign to "Quiet the Food Noise," a Key Barrier for Individuals Seeking Weight Loss. Currax Pharmaceuticals LLC. September 24, 2024. Accessed January 3, 2025. https://www.prnewswire.com/news-releases/currax-pharmaceuticals-unveils-new-disease-awareness-campaign-to-quiet-the-food-noise-a-key-barrier-for-individuals-seeking-weight-loss-302257022.html
3. Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study. Currax Pharmaceuticals LLC. August 27, 2024. Accessed January 3, 2025. https://www.prnewswire.com/news-releases/currax-pharmaceuticals-contravemysimba-demonstrates-positive-cardiovascular-safety-in-a-large-real-world-evidence-study-302231103.html